PET/CT评估晚期NSCLC多模式治疗疗效与毒性的现状与未来方向
本文为叙述性综述,探讨18F-FDG PET/CT在晚期非小细胞肺癌(NSCLC)免疫检查点抑制剂(ICI)治疗时代的应用。综述涵盖ICI治疗范式、CT标准演变、ICI相关新现象及混合成像在诊断、治疗计划、疗效与毒性评估中的现状与局限。结论指出基于现行标准的免疫治疗疗效评估有临床价值但存在固有局限,需将PET疗效标准纳入前瞻性随机对照试验并实现标准统一。
要点
- FDG PET/CT广泛用于局部晚期NSCLC肿瘤体积勾画。
- 基于现行标准的免疫治疗疗效评估有高临床价值但存在固有局限。
- 需将PET疗效标准纳入前瞻性随机对照试验并统一标准。
核心结论
- ICI时代带来治疗反应评估新挑战及伴随新全身副作用的新现象。
- FDG PET/CT广泛用于局部晚期疾病肿瘤体积勾画,但基于现行标准的免疫治疗反应评估有固有局限。
- 需将PET疗效标准全面纳入前瞻性随机对照试验并在各种PET疗效标准间实现统一,以加强临床实施和广泛使用。
研究设计与样本
- 叙述性综述,涵盖ICI治疗范式、CT标准演变、ICI相关新现象及混合成像在晚期NSCLC诊断、治疗计划、疗效与毒性评估中的现状、局限与未来方向。
主要发现
- ICI改变了晚期NSCLC治疗格局并带来治疗反应评估与新型全身副作用观察的新挑战。
- FDG PET/CT广泛用于局部晚期疾病肿瘤体积勾画。
- 基于现行标准的免疫治疗反应评估有高临床价值但存在固有局限。
- 近年已提出对既有(PET)/CT标准的修改以提供更精细的反应评估方法。
临床怎么用
- FDG PET/CT可用于局部晚期NSCLC肿瘤体积勾画。
- 免疫治疗反应评估可基于现行标准进行,但需认识其固有局限。
- 可参考近年对既有(PET)/CT标准的修改以进行更精细的反应评估。
局限性
- 基于现行标准的免疫治疗反应评估存在固有局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative review on the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in the ever-evolving treatment landscape of advanced NSCLC is presented. METHODS: This comprehensive review will begin with an introduction into current treatment paradigms incorporating ICIs; the evolution of CT-based criteria; moving onto novel phenomena observed with ICIs and the current state of hybrid imaging for diagnosis, treatment planning, evaluation of treatment efficacy and toxicity in advanced NSCLC, also taking into consideration its limitations and future directions. CONCLUSIONS: The advent of ICIs marks the dawn of a new era bringing forth new challenges particularly vis-à-vis treatment response assessment and observation of novel phenomena accompanied by novel systemic side effects. While FDG PET/CT is widely adopted for tumor volume delineation in locally advanced disease, response assessment to immunotherapy based on current criteria is of high clinical value but has its inherent limitations. In recent years, modifications of established (PET)/CT criteria have been proposed to provide more refined approaches towards response evaluation. Not only a comprehensive inclusion of PET-based response criteria in prospective randomized controlled trials, but also a general harmonization within the variety of PET-based response criteria is pertinent to strengthen clinical implementation and widespread use of hybrid imaging for response assessment in NSCLC.
引用
- Eze C, Schmidt-Hegemann NS, Sawicki LM, et al. PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging. 2021. PMID: 33760957. doi:10.1007/s00259-021-05211-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。